Date: 2016-05-09
Type of information: Initiation of the trial
phase: 1
Announcement: initiation of the trial
Company: Galapagos (Belgium)
Product: GLPG2451
Action
mechanism: CFTR potentiator. GLPG2451 is a CFTR potentiator. Galapagos and Abbvie aim to develop a triple CFTR combination therapy to address 90% of patients with CF. In order to bring a more effective therapy to patients, the companies have developed multiple candidates and backups for each of the three components of a potential triple combination. GLPG2451 is the second potentiator and the third compound in the portfolio to enter the clinic.
Disease: cystic fibrosis
Therapeutic area: Rare diseases - Genetic diseases
Country: Belgium, The Netherlands
Trial details:
Latest
news: * On May 9, 2016, Galapagos announced the start of a Phase 1 study with potentiator GLPG2451 for cystic fibrosis (CF). Following GLPG1837, GLPG2451 is the second potentiator compound in Galapagos' extended CF-portfolio to enter clinical trials. Galapagos is conducting a randomized, double-blind, placebo-controlled study over a range of doses of GLPG2451 in healthy volunteers in Belgium and the Netherlands and expects topline results in Q4 2016. The start of this Phase 1 study triggers a $10 million milestone payment from AbbVie under the recently expanded global collaboration agreement.
